133 related articles for article (PubMed ID: 30828786)
1. Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial nonmedullary thyroid carcinoma Italian families.
Cirello V; Colombo C; Persani L; Fugazzola L
Int J Cancer; 2019 Jul; 145(2):600. PubMed ID: 30828786
[No Abstract] [Full Text] [Related]
2. Authors' reply to: Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families. International Journal of Cancer 2019; in press.
Ye F; Gao H; Xiao L; Ding H; Huang Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Jul; 145(2):601-602. PubMed ID: 30828792
[No Abstract] [Full Text] [Related]
3. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
4. Is familial nonmedullary thyroid carcinoma more aggressive than sporadic nonmedullary thyroid carcinoma?
Malchoff CD; McDonald TJ
Thyroid; 2014 Apr; 24(4):782-3. PubMed ID: 24494807
[No Abstract] [Full Text] [Related]
5. Reply to the Letter to the Editor 'Germline-somatic fluidity in guiding patient care. Reply to the Letter to the Editor "Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients" by J. C. Rubinstein et al.' by E. Hahn & G. S. Charames.
Christison-Lagay ER; Rubinstein JC
Ann Oncol; 2020 Aug; 31(8):1090-1091. PubMed ID: 32428551
[No Abstract] [Full Text] [Related]
6. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
7. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
8. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
[TBL] [Abstract][Full Text] [Related]
9. Aggressiveness in familial nonmedullary thyroid carcinoma--the controversy continues.
Mazeh H; Sippel RS
Thyroid; 2014 Apr; 24(4):783-4. PubMed ID: 24660808
[No Abstract] [Full Text] [Related]
10. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Simeone P; Alberti S
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27418631
[No Abstract] [Full Text] [Related]
11. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Carvajal-Carmona LG; Tomlinson I; Sahasrabudhe R
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27154966
[No Abstract] [Full Text] [Related]
12. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway.
Frich L; Glattre E; Akslen LA
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):113-7. PubMed ID: 11219767
[TBL] [Abstract][Full Text] [Related]
13. Biological behavior and prognosis of familial papillary thyroid carcinoma.
Ito Y; Kakudo K; Hirokawa M; Fukushima M; Yabuta T; Tomoda C; Inoue H; Kihara M; Higashiyama T; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Surgery; 2009 Jan; 145(1):100-5. PubMed ID: 19081481
[TBL] [Abstract][Full Text] [Related]
14. Evidence is not sufficient to recommend a more aggressive approach to familial nonmedullary thyroid cancer.
Benbassat C
Thyroid; 2014 Apr; 24(4):781-2. PubMed ID: 24295148
[No Abstract] [Full Text] [Related]
15. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.
Liu C; Yu Y; Yin G; Zhang J; Wen W; Ruan X; Li D; Zhang S; Cai W; Gao M; Chen L
Biochem Biophys Res Commun; 2017 Jan; 482(4):590-596. PubMed ID: 27864143
[TBL] [Abstract][Full Text] [Related]
16. G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.
Ruiz-Ferrer M; Fernández RM; Navarro E; Antiñolo G; Borrego S
Thyroid; 2016 Jul; 26(7):987-8. PubMed ID: 27245704
[No Abstract] [Full Text] [Related]
17. The incidence of familial nonmedullary thyroid cancer in a large case series.
Zivaljevic V; Paunovic I; Diklic A; Krgovic K; Kalezic N; Kazic M; Tatic S; Savic D; Stojanovic D; Perunovic R
Acta Chir Belg; 2008; 108(3):328-32. PubMed ID: 18710108
[TBL] [Abstract][Full Text] [Related]
18. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment.
Takami H; Ozaki O; Ito K
Arch Surg; 1996 Jun; 131(6):676. PubMed ID: 8645080
[No Abstract] [Full Text] [Related]
19. Family with nonmedullary thyroid neoplasms.
Kobayashi K; Tanaka Y; Ishiguro S; Mori T; Mitani Y; Shigemasa C
J Surg Oncol; 1995 Apr; 58(4):274-7. PubMed ID: 7723373
[TBL] [Abstract][Full Text] [Related]
20. Second generation of familial nonmedullary thyroid carcinoma: A meta-analysis on the clinicopathologic features and prognosis.
Zhou YM; Luo H; Gou JX; Zhao WJ; Dai WY; Zhu J; Li ZH
Eur J Surg Oncol; 2017 Dec; 43(12):2248-2256. PubMed ID: 28942234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
